Leerink Partnrs Predicts Lower Earnings for Pyxis Oncology

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Leerink Partnrs reduced their Q3 2024 EPS estimates for shares of Pyxis Oncology in a research report issued to clients and investors on Tuesday, October 15th. Leerink Partnrs analyst J. La. Rosa now anticipates that the company will post earnings per share of ($0.35) for the quarter, down from their previous estimate of ($0.28). The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.07) per share. Leerink Partnrs also issued estimates for Pyxis Oncology’s Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.07) EPS, FY2025 earnings at ($1.33) EPS, FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($1.17) EPS and FY2028 earnings at ($1.07) EPS.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04.

A number of other equities research analysts have also weighed in on PYXS. Royal Bank of Canada restated an “outperform” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Thursday, September 19th. Stifel Nicolaus started coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They issued a “buy” rating and a $10.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research note on Friday, August 16th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $9.00.

Pyxis Oncology Trading Up 16.1 %

Shares of NASDAQ PYXS opened at $3.75 on Friday. Pyxis Oncology has a 1-year low of $1.35 and a 1-year high of $6.85. The stock’s 50-day moving average is $3.54 and its 200 day moving average is $3.78. The stock has a market cap of $222.83 million, a price-to-earnings ratio of -3.02 and a beta of 1.27.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PYXS. Fullcircle Wealth LLC purchased a new position in shares of Pyxis Oncology during the second quarter valued at about $40,000. SG Americas Securities LLC purchased a new position in shares of Pyxis Oncology in the 3rd quarter valued at approximately $58,000. The Manufacturers Life Insurance Company bought a new stake in shares of Pyxis Oncology during the second quarter valued at approximately $65,000. Cetera Advisors LLC purchased a new stake in Pyxis Oncology in the first quarter worth $100,000. Finally, Schulhoff & Co. Inc. lifted its position in Pyxis Oncology by 90.9% during the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock valued at $139,000 after buying an additional 20,000 shares during the period. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.